Sarepta CEO: Study shows we're on the right path to treat muscular dystrophy

Doug Ingram, Sarepta Therapeutics president and CEO, talks about the company's positive study results for treatment of Duchenne muscular dystrophy.
01:15
Wed, Sep 6 20178:20 AM EST